---

Bile Metabolism and Its Clinical Significance

Sources: Sleisenger & Fordtran's Gastrointestinal and Liver Disease, Harper's Illustrated Biochemistry, Medical Physiology (Boron & Boulpaep), Tietz Textbook of Laboratory Medicine, Harrison's Principles of Internal Medicine 22E

---

1. Overview: What Is Bile?

• Bile acids (primary drivers of bile flow)
• Bile pigments (mainly bilirubin)
• Cholesterol, phospholipids (especially phosphatidylcholine)
• Electrolytes, water, glutathione
• Conjugated metabolites and xenobiotics

---

2. Bile Acid Synthesis

2.1 From Cholesterol to Primary Bile Acids

• Cholic acid (CA): Hydroxyl groups at C-3, C-7, C-12 (trihydroxy)
• Chenodeoxycholic acid (CDCA): Hydroxyl groups at C-3, C-7 (dihydroxy)
• These are called primary bile acids

2.2 Pool Size and Kinetics

2.3 Conjugation (Amidation)

---

3. Secondary Bile Acid Formation (Gut Microbiota)

• Cholic acid → Deoxycholic acid (DCA)
• Chenodeoxycholic acid → Lithocholic acid (LCA)

• Deconjugation (removal of glycine/taurine)
• Epimerization of 3α- and 7α-hydroxyl groups
• Hepatic reduction yields ursodeoxycholic acid (UDCA) from 7-oxo lithocholic acid

---

4. The Enterohepatic Circulation

Steps:

1. Hepatic secretion - Conjugated bile acids are actively pumped into bile canaliculi via BSEP (ABCB11) - the bile salt export pump
2. Gallbladder storage - Bile is concentrated ~5-20x
3. Postprandial release - CCK triggers gallbladder emptying into duodenum
4. Intestinal function - Bile acids form mixed micelles with cholesterol, phospholipids, free fatty acids, monoglycerides; critical micellar concentration ~2 mmol/L
5. Ileal reabsorption - Active transport via ASBT (SLC10A2) in terminal ileum absorbs ~95% of bile acids
6. Portal return - Via portal blood to liver
7. Hepatic re-uptake - Via NTCP (SLC10A1) (Na+-dependent, >80% of conjugated) and OATP1B1/OATP1B3 (Na+-independent)

"The presence of an ileal active transport system and enterohepatic circulation dissociates hepatic bile acid secretion from bile acid synthesis, thereby improving the efficiency of intestinal nutrient digestion and absorption." - Sleisenger & Fordtran, p. 1205

---

5. Regulation of Bile Acid Synthesis

---

6. Hepatic Bile Formation and Transport Proteins

• Bile acid-dependent bile flow (~60%): Driven by active secretion of bile acids via BSEP
• Bile acid-independent bile flow (~40%): Driven by glutathione, bicarbonate, and inorganic electrolyte secretion

---

7. Bilirubin Metabolism

7.1 Production

• ~80% from senescent RBC hemoglobin breakdown
• Remainder from myoglobin, cytochromes, and ineffective erythropoiesis
• Heme → biliverdin (by heme oxygenase-1, rate-limiting step)
• Biliverdin → bilirubin (by biliverdin reductase)
• Bilirubin is water-insoluble and circulates bound to albumin as unconjugated (indirect) bilirubin

7.2 Hepatic Uptake

• Bilirubin is removed from albumin at the sinusoidal surface by a saturable facilitated transport system (OATP1B1, OATP1B3)
• Once inside hepatocytes, bilirubin binds ligandin (glutathione S-transferase) to prevent re-entry into blood

7.3 Conjugation

• UDP-glucuronosyltransferase (UGT1A1) in the ER catalyzes conjugation with glucuronic acid:
  • Bilirubin → bilirubin monoglucuronide → bilirubin diglucuronide (dominant form in bile)
• Diglucuronide = "direct-reacting" bilirubin (water-soluble)
• Phenobarbital induces UGT1A1 (used therapeutically in neonatal jaundice) - Harper's Biochemistry, p. 334

7.4 Secretion and Intestinal Fate

• Conjugated bilirubin secreted into bile via MRP2 (ABCC2) - the rate-limiting step
• Intestinal bacteria reduce conjugated bilirubin to colorless urobilinogen
• ~20% urobilinogen absorbed → portal blood → liver re-excretes most; kidneys excrete ~20% → gives urine its yellow color (urobilin upon oxidation)
• Remainder → stercobilin → colors feces brown

---

8. Micelle Formation and Fat Absorption

• Bile acids are amphipathic - they align at water-lipid interfaces and reduce surface tension
• In aqueous solution they aggregate to form micelles (~5 nm diameter)
• Mixed micelles incorporate cholesterol, phospholipids, free fatty acids, monoglycerides, and fat-soluble vitamins (A, D, E, K)
• Critical micellar concentration: ~2 mmol/L
• Micelles ferry lipid digestion products to the mucosal brush border for absorption - Tietz Textbook, p. 1973

---

9. Clinical Significance

9.1 Jaundice - Classification

9.2 Genetic Disorders of Bilirubin Conjugation

9.3 Cholestasis

• Intrahepatic cholestasis - functional defect at hepatocyte level
• Extrahepatic cholestasis - mechanical obstruction in biliary tract

1. Defects in bile acid formation (synthesis and conjugation)
2. Defects in membrane transport of bile acids
3. Disturbances in bacterial transformation (SIBO - deconjugation, dehydroxylation)
4. Disturbances in movement through or between organs - Sleisenger & Fordtran, p. 1207

9.4 Progressive Familial Intrahepatic Cholestasis (PFIC)

9.5 Intrahepatic Cholestasis of Pregnancy (ICP)

• Proposed etiology: Interference with bile acid transport across canalicular membrane
• Presents in 2nd-3rd trimester with pruritus
• Serum bile acids > 40 μmol/L = severe ICP; strong association with fetal complications
• Reference range in pregnancy: 0.3-10 μmol/L
• Management: Delivery recommended at 36-37 weeks when bile acids ≥ 100 μmol/L to prevent stillbirth - Tietz Textbook, p. 1973-1974; Goldman-Cecil Medicine

9.6 Bile Acid Malabsorption (BAM)

• Ileal resection or disease (e.g., Crohn's) → bile acid loss to colon → secretory diarrhea (type 3 BAM) if small loss; steatorrhea if large resection
• Congenital ASBT deficiency (SLC10A2 mutations) → primary bile acid malabsorption with congenital diarrhea
• SIBO → premature deconjugation → reduced micellar function → fat malabsorption

9.7 Bile Acid Synthesis Defects (Inherited)

• Steatorrhea + fat-soluble vitamin deficiency (A, D, E, K)
• Neonatal hepatitis / cholestasis
• Neurological defects (cerebrotendinous xanthomatosis if CYP27A1 defect)
• Normal or low serum GGTP (distinguishes from MDR3 deficiency)
• Treatment: Primary bile acid replacement (cholic acid or chenodeoxycholic acid) - Sleisenger & Fordtran, p. 1209

9.8 Hepatocyte Dysfunction (Liver Disease)

• ↓ Bile acid synthesis → low primary bile acid concentrations
• ↓ Portal extraction → ↑ serum bile acids (particularly postprandial)
• ↓ Ratio of primary:secondary bile acids
• ↑ Unconjugated and sulfated bile acid forms

• ↓ Primary bile acid delivery to intestine → ↓ secondary bile acid production
• ↑ Ratio of primary:secondary bile acids in serum

9.9 FXR as a Therapeutic Target

• NAFLD/NASH - FXR agonists reduce hepatic lipogenesis (via SREBP1c) and inflammation
• Type 2 diabetes - FXR signaling improves insulin sensitivity (via PEPCK/G6Pase inhibition, glycogen synthesis)
• Metabolic syndrome - derangement of the gut-liver axis promotes SIBO and systemic inflammation
• Obeticholic acid (FXR agonist) - approved for primary biliary cholangitis; studied in NASH

9.10 Gallstone Disease

• Cholesterol gallstones (80%): Result from supersaturation of bile with cholesterol relative to bile acids + phospholipids; ABCG5/ABCG8 mutations increase cholesterol secretion; MDR3 mutations reduce phospholipid secretion
• Pigment gallstones: Excess unconjugated bilirubin precipitation (hemolytic anemias, ileal disease)
• Bile acid therapy (UDCA) can dissolve small cholesterol gallstones by expanding the bile acid pool and reducing cholesterol saturation

---

10. Bile Acid Measurement: Laboratory Perspective

---

11. Key Pharmacological Applications

---

Summary Diagram of Bile Metabolism

Cholesterol
    ↓ CYP7A1 (classical) / CYP27A1+CYP7B1 (alternative)
PRIMARY BILE ACIDS: Cholic acid (CA) + Chenodeoxycholic acid (CDCA)
    ↓ + Glycine or Taurine (UGT conjugation)
Glyco-CA / Tauro-CA / Glyco-CDCA / Tauro-CDCA
    ↓ BSEP secretion into canaliculi
BILE DUCT → GALLBLADDER → DUODENUM
    ↓ Intestinal bacterial 7α-dehydroxylation
SECONDARY BILE ACIDS: Deoxycholic acid + Lithocholic acid
    ↓ ~95% absorbed via ASBT (terminal ileum)
PORTAL VEIN → LIVER (NTCP/OATP re-uptake)
    ↓ ~5% lost in feces (replaced by new synthesis)

BILIRUBIN METABOLISM:
Heme → (HO-1) → Biliverdin → (BVR) → Bilirubin (unconjugated, albumin-bound)
    ↓ Hepatic uptake (OATP) → Ligandin binding
    ↓ UGT1A1 conjugation
Bilirubin diglucuronide (direct) → MRP2 → Bile → Intestine
    ↓ Bacteria
Urobilinogen → Urobilin (urine, yellow) + Stercobilin (feces, brown)

---

1. The enterohepatic circulation is the master regulator of bile acid homeostasis - disruption at any step causes disease
2. Bilirubin conjugation (UGT1A1) and secretion (MRP2) are sequential rate-limiting steps - genetic defects at each produce distinct syndromes
3. NTCP on hepatocytes is also the HBV/HDV entry receptor - creating therapeutic opportunities
4. FXR is a pleiotropic metabolic regulator linking bile acids to glucose homeostasis, lipid metabolism, and gut microbiota - a major drug target
5. Serum bile acids > 40 μmol/L in pregnancy indicate severe ICP requiring early delivery